Skip to main content
Premium Trial:

Request an Annual Quote

Hitachi, DSI Collaborate on Method to Manage Growth of Sequencing Data

NEW YORK (GenomeWeb News) – Hitachi Asia and Data Storage Institute today announced an extension of a collaboration to develop a data compression technique in order to manage the ever-growing amount of genomic sequencing data.

Researchers at DSI, a research institute of Singapore's Agency for Science, Technology, and Research (A*STAR), are studying how sequencing data is being optimized by researchers from the Genome Institute of Singapore, also an A*STAR institute. Building on their earlier work, Hitachi and DSI will now seek to address the shortfalls identified in the current data storage models by designing a genome data compression method that reduces data storage capacity needs, quickens compression speeds, and lower storage costs, they said.

In their earlier collaboration Hitachi and DSI discovered patterns of typical genome data transaction "that would enable current storage systems to function optimally," they said.

"By raising compression capacity, we can envision smaller genome sequencing facilities to handle petabytes of data in a year compared to current terabytes levels which are mostly restricted to large genome sequencing centers due to storage limitations," DSI Executive Director Pantelis Alexopoulos said in a statement.

Terms of the agreement were not disclosed.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.